Immtech Pharamaceuticals Immtech company immtech investors Immtech business development immtech contact Immtech technology Immtech pipeline
Immtech drug discovery program  
Immtech Hepatitis C Immtech Staph Infections Immtech fungal diseases  



resistant infections are growing
Immtech has identified a unique class of compounds that show promise in fighting a range of bacterial infections.

Several bacteria have emerged as significant health threats in recent years;

  • Methicillin-resistant Staphylococcus aureus (MRSA) can cause hospital-acquired
    infection as well as serious illness in ambulatory individuals.
  • Vancomycin-resistant Enterococcus leads to hospital-acquired infection.
  • Pneumococcus is a frequent cause of pneumonia which has also developed
    resistance to drugs.
  • Staphylococcus can lead to multidrug-resistant (MDR) infections.
According to a May 2006 Espicom Business Intelligence Report, the market for anti-MRSA
antibiotics is expected to reach US$2 billion in 2006.

Immtech's proprietary chemical library has yielded a unique class of aromatic dications
with potent activity against a panel of methicillin-sensitive staph (Staphylococcus aureus,
MSSA), methicillin-resistant staph (MRSA) and vancomycin-resistant enterococcus (VRE), in
addition to a broad range of other gram positive aerobic and anaerobic bacteria. A second
round of testing of a more focused subclass of compounds further refined the structure-activity
relationships for this new class, and provided a launch point for advanced in vivo testing.

Terms of Use | Privacy Policy
© 2008 Immtech. All Rights Reserved